Dr. Reddy's Laboratories - RU3QFY2013 Dr. Reddy’s Laboratories (DRL) reported more or less just-in 3QFY2013 top-line and bottom-line performance. The company’s net sales increased by 3.5% yoy (23% adjusted for the base effect). The growth came in on back of 24% yoy (adjusted) in the US and Emerging Markets. On the EBIT margins came in at 15.0% V/s expected 15.8%. Consequently the net profit came in at `363cr, a dip of 29.1%, mostly in line with expectations of `339cr. DRL reported net sales of `2,865cr for 3QFY2013, registering 23.0% yoy growth, which was a tad lower than our estimate of `2,700cr. The U.S. and Emerging markets grew by 24% yoy (adjusted) were the key growth drivers for the company. The domestic market reported a strong growth of 12.0% yoy. On the positive side the PSAI segment posted a robust growth of 28.0% yoy during the quarter. The company’s E...
The content on this blog gives the daily fundamental and technical outlook about the Indian Financial Markets. Reader discernment is called for !!